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Abstract
Objective: In this prospective study we investigated the role of plasma levels of soluble urokinase plasminogen activator receptor 
(suPAR) in children with urinary tract infection.
Material and methods: We measured the levels of plasma suPAR during admission in 42 children with suspected acute pyelonephritis 
and compared the results to acute DMSA scintigraphy.
Results: The mean level of plasma suPAR at admission was significantly elevated in children with renal involvement (7.3 ng/ml) 
assessed by the DMSA scintigraphy compared to children without renal involvement (4.4 ng/ml, P = 0.010). The positive predictive 
value of suPAR seems high, since all patients without renal involvement had low suPAR values. During treatment the mean level of 
plasma suPAR decreased.
Conclusion: We conclude that plasma suPAR could be of clinical use for the diagnosis of acute pyelonephritis and that high levels of 
plasma suPAR might reflect the level of renal involvement and could therefore be a new indicator for renal scarring.
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Introduction
Urinary  tract  infection  (UTI)  is  a  very  common 
  childhood  infection,  which  normally  resolves 
after  antibiotic  therapy  without  further    morbidity. 
  However, in children with UTI involving the renal 
parenchyma, 10%–20% will develop chronic   kidney 
disease,1    associated  with  abnormal  findings  on 
  dimercaptosuccinic  acid  (DMSA)  scintigraphy  six 
months after the infection, so called renal scarring.2
Soluble  uPAR  (urokinase  plasminogen  receptor 
activator or suPAR) is a new and promising inflam-
matory biomarker and has demonstrated prognostic 
value in various infectious diseases such as tubercu-
losis, HIV infection and streptococcal bacteremia.3,4 
Elevated levels have recently also been associated 
with increased risk of cardiovascular disease, type 2 
diabetes and cancer in the general population.5 So far 
only a few studies have been published on suPAR as 
a biomarker for infections in the paediatric popula-
tion, and little is known about the kinetics of suPAR.6 
Finally, mice knockout studies have shown a crucial 
role of uPAR in the host defence against experimental 
acute pyelonephritis.7
We  aimed  to  investigate  whether  there  is  a 
  relationship  between  plasma  suPAR  and  renal 
  involvement  assessed  by  DMSA  scintigraphy  in 
children with acute pyelonephritis. Furthermore, we 
wished to determine the response of plasma suPAR to 
relevant treatment of the infection.
Materials and Methods
Blood samples from 42 patients were analysed for 
this study. Inclusion criterias: Children , 15 years 
of age suspected of having acute pyelonephritis, ie, 
fever (.38.5 °C), malaise, leucocyturia and positive 
urine culture (more than 104 CFU). Blood samples 
were collected for suPAR measurement at admission. 
The children were aged 2 months—14 years (average: 
7 years) with a girl:boy ratio of 34:8. The local ethical 
committee approved this study and informed consent 
was obtained from parents and/or patients. For the 
purpose of comparing the suPAR levels in children 
with UTI with a group of non-infected children, we 
analysed plasma suPAR levels in 19 out clinic patients 
with well-treated asthma.
Within  5  days  of  admission  renal  parenchymal 
involvement  was  assessed  by  DMSA  scintigraphy. 
The results were evaluated on the 5 level scale of 
  severity (proposed by Benador et al8) by 2   specialists, 
who were neither aware of the children’s   condition 
nor  of  test  results.  All  patients  received  treatment 
for    suspected  acute  pyelonephritis    consisting  of 
  intravenous ampicillin 100 mg/kg/day and   gentamicine 
6 mg/kg/day. SuPAR levels were determined using 
the    suPARnostic  ELISA  (ViroGates,  Copenhagen, 
  Denmark).    Comparison  of  suPAR  concentrations 
between groups was determined using Mann   Whitney 
U-test. Changes in patient biomarker concentrations 
over time were determined using the paired   sample 
t-test.  Statistical  analysis  was  carried  out  using 
SSPS v11 and graphs drawn using Graph Pad Prism. 
A P-value ,0.05 was considered significant.
Results
Figure  1  illustrates  the  subgroups  of  the  42 
patients:  (1)  patients  with  uptake  defects  on  acute 
scintigrams (N = 9), (2) patients with normal acute 
scintigrams (N = 15) and (3) patients who did not 
receive acute scintigraphy, due to former UTI with 
scarring (N = 18). Figure 2 shows the plasma suPAR 
levels for the 3   subgroups. Patients with DMSA posi-
tive UTI (1) had significantly higher median plasma 
suPAR level (7.3 ng/ml) than patients with DMSA 
42 patients
9 patients with
DMSA positive UTI
15 patients with
DMSA negative UTI
18 patients with recurrent
UTI and no DMSA
Figure 1. Flowchart of participants, who were divided into 3 groups: 
(1) DMSA positive UTI = uptake defects on acute scintigrams; (2) DMSA 
negative UTI = normal acute scintigrams; (3) patients with no acute scin-
tigraphy due to former UTI with scarring.Plasma suPAr in children with UTI
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negative UTI (2) (4.4 ng/ml, P = 0.010) and patients 
with   recurrent UTI and no new DMSA scintigraphy 
(3) (4.0 ng/ml, P = 0.005). The median plasma suPAR 
levels  in  these  3  subgroups  were  all    significantly 
higher  than  in    children  from  the  out  patient  clinic 
with  asthma  (4)  (2.3  ng/ml,  N  =  19,  P  ,  0.001). 
  Furthermore  we    analysed  suPAR  levels  following 
treatment   initiation and the median level was 4.4 ng/
ml on day 1   (admission)   falling to 3.7 ng/ml (n = 23) 
on day 3 and 2.9 ng/ml on day 5 (n = 8). A paired 
sample t-test for suPAR levels in all patients showed a 
trend towards a decrease in suPAR (P = 0.053).
C-reactive protein (CRP) and procalcitonin (PCT) 
were also measured at admission. Figure 3 displays 
the  CRP  levels  in  the  3  groups  of  children  with 
UTI  (n  =  42)  and  we  found  a  significant  positive 
  correlation of the suPAR levels with CRP, Pearson 
correlation = 0.492, P , 0.01. Comparison of suPAR 
and PCT levels in this group yielded a non-  significant 
positive  correlation  of  0.300  (n  =  14),  probably 
because of the low sample number.
Discussion
Despite the relatively low number of  patients included 
in this study, we found significant higher levels of 
plasma  suPAR  in  patients  with  positive  DMSA. 
This suggests that suPAR is a powerful marker of 
inflammation  concordant  with  previous  studies  of 
suPAR. Noticeable for suPAR in this study and also 
prior, is a relatively small increase in suPAR during 
severe inflammation compared to the huge increases 
seen for CRP. The smaller increase of suPAR does 
not make it a poorer inflammatory marker compared 
to CRP. The nature of suPAR seems to be less fluctuat-
ing and a two-fold increase or more is usually enough 
to predict inflammation. We suggest suPAR as a pos-
sible complementary test to CRP with a promising 
positive predictive value.
In the group of patients with positive DMSA there 
are 2 outliers with rather low suPAR levels. This could 
be explained by for example congenital abnormali-
ties, but we can of course not rule out the possibility 
of these being true false negative samples.
We  conclude  that  plasma  suPAR  levels  among 
children with positive DMSA scintigraphy were sig-
nificantly elevated at admission. Since suPAR levels 
reflect immune activation and inflammation and our 
study shows an association between the suPAR level 
and acute DMSA scintigraphic findings, we suggest 
that the severity of the infection may be measured 
using suPAR. Further and larger studies are needed 
to determine whether high plasma suPAR levels are 
prognostic for the development of renal scarring and 
chronic renal disease.
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Figure 2. suPAr levels (ng/ml) at admission in patients with UTI and: 
positive DMSA (1), negative DMSA (2) and recurrent UTI with no DMSA 
(3).  For  comparison,  the  mean  suPAr  level  of  the  control  group  is 
  illustrated (4).
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Figure 3. crP levels (mg/l) at admission in patients with UTI and:   positive 
DMSA, negative DMSA or recurrent UTI with no DMSA.publish with Libertas Academica and 
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